Monthly Archives: August 2012

Biotech’s Capital Intensity Challenge: A Post-Mortem on 2007’s Biggest Deals
August 29, 2012

“Raise all the money you can whenever you can, and then raise some more”.  “The more a company raises, the more successful it is”.  Resumes boasting about how much an executive has raised in their prior companies.  These sentiments are

5 Comments

Big BioPharma Stock Buybacks: Are There Better Alternatives?
August 22, 2012

Big Pharma remains a highly profitable cash cow in spite of its well-known R&D challenges and perennial patent cliffs.  One of the biggest questions their Boards must wrestle with is what to do with all the cash. In recent years,

5 Comments

The Quiet Outperformance of Recent Biotech IPOs
August 1, 2012

Biotech IPOs have long been viewed with skeptism, especially over the past few years in comparison to the high-flying media darlings in the Tech space.  But recently a number of the social media phenoms have fallen from grace: Groupon is

Leave a comment